Advised an independent international French-based pharmaceutical company, in its acquisition of a leading global biotechnology company focused on rare diseases, a transaction valued at USD 2.4 billion; and its acquisition of a pharmaceuticals’ oncology business including its commercial, clinical and research-stage oncology portfolio for up to USD 2 billion, including an upfront payment of USD 1.8 billion and a potential USD 200 million in regulatory milestone, plus royalties.*